- Home
- TROO vs ATOS Comparison
TROO vs ATOS Comparison
Compare TROO & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TROO
- ATOS
- Stock Information
- Founded
- TROO 2005
- ATOS 2009
- Country
- TROO Hong Kong
- ATOS United States
- Employees
- TROO N/A
- ATOS N/A
- Industry
- TROO Radio And Television Broadcasting And Communications Equipment
- ATOS Biotechnology: Pharmaceutical Preparations
- Sector
- TROO Technology
- ATOS Health Care
- Exchange
- TROO Nasdaq
- ATOS Nasdaq
- Market Cap
- TROO 91.6M
- ATOS 96.8M
- IPO Year
- TROO N/A
- ATOS 2012
- Fundamental
- Price
- TROO $0.66
- ATOS $0.60
- Analyst Decision
- TROO
- ATOS Strong Buy
- Analyst Count
- TROO 0
- ATOS 3
- Target Price
- TROO N/A
- ATOS $7.00
- AVG Volume (30 Days)
- TROO 459.2K
- ATOS 542.4K
- Earning Date
- TROO 04-28-2025
- ATOS 05-12-2025
- Dividend Yield
- TROO N/A
- ATOS N/A
- EPS Growth
- TROO N/A
- ATOS N/A
- EPS
- TROO N/A
- ATOS N/A
- Revenue
- TROO $4,344,000.00
- ATOS N/A
- Revenue This Year
- TROO N/A
- ATOS N/A
- Revenue Next Year
- TROO N/A
- ATOS N/A
- P/E Ratio
- TROO N/A
- ATOS N/A
- Revenue Growth
- TROO 14.77
- ATOS N/A
- 52 Week Low
- TROO $0.71
- ATOS $0.63
- 52 Week High
- TROO $4.89
- ATOS $2.31
- Technical
- Relative Strength Index (RSI)
- TROO 29.82
- ATOS 32.35
- Support Level
- TROO $0.73
- ATOS $0.66
- Resistance Level
- TROO $1.53
- ATOS $0.71
- Average True Range (ATR)
- TROO 0.09
- ATOS 0.04
- MACD
- TROO 0.01
- ATOS -0.01
- Stochastic Oscillator
- TROO 7.84
- ATOS 0.00
About TROO TROOPS Inc.
TROOPS Inc is a conglomerate group of various businesses with its headquarters based in Hong Kong. The group is principally engaged in money lending business in Hong Kong providing mortgage loans to high quality target borrowers, property investment to generate additional rental income and the development, operation and management of an online financial marketplace that provides one-stop financial technology solutions including API services by leveraging artificial intelligence, large data and blockchain, and cloud computing (SaaS). It derives revenue from Hong Kong and Australia. Majority of its revenue generates from domestic market.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.